<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Stroke</journal-id><journal-id journal-id-type="iso-abbrev">J Stroke</journal-id><journal-id journal-id-type="publisher-id">JOS</journal-id><journal-title-group><journal-title>Journal of Stroke</journal-title></journal-title-group><issn pub-type="ppub">2287-6391</issn><issn pub-type="epub">2287-6405</issn><publisher><publisher-name>Korean Stroke Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4325636</article-id><article-id pub-id-type="doi">10.5853/jos.2015.17.1.17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Special Review</subject><subj-group subj-group-type="heading"><subject>Small Vessel Disease I</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Cerebral Amyloid Angiopathy: Emerging Concepts </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yamada</surname><given-names>Masahito</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.</aff><author-notes><corresp>Correspondence: Masahito Yamada. Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8640, Japan. Tel: +81-76-265-2290, Fax: +81-76-234-4253, <email>m-yamada@med.kanazawa-u.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>1</month><year>2015</year></pub-date><volume>17</volume><issue>1</issue><fpage>17</fpage><lpage>30</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>15</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2015 Korean Stroke Society</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Cerebral amyloid angiopathy (CAA) involves cerebrovascular amyloid deposition and is classified into several types according to the amyloid protein involved. </plain></SENT>
<SENT sid="2" pm="."><plain>Of these, sporadic amyloid β-protein (Aβ)-type CAA is most commonly found in older individuals and in patients with Alzheimer's disease (AD). </plain></SENT>
<SENT sid="3" pm="."><plain>Cerebrovascular Aβ deposits accompany functional and pathological changes in cerebral blood vessels (CAA-associated vasculopathies). </plain></SENT>
<SENT sid="4" pm="."><plain>CAA-associated vasculopathies lead to development of hemorrhagic lesions [lobar intracerebral macrohemorrhage, cortical microhemorrhage, and cortical superficial siderosis (cSS)/focal convexity subarachnoid hemorrhage (SAH)], ischemic lesions (cortical infarction and ischemic changes of the white matter), and encephalopathies that include subacute leukoencephalopathy caused by CAA-associated inflammation/angiitis. </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, CAA is related to dementia, stroke, and encephalopathies. </plain></SENT>
<SENT sid="6" pm="."><plain>Recent advances in diagnostic procedures, particularly neuroimaging, have enabled us to establish a clinical diagnosis of CAA without brain biopsies. </plain></SENT>
<SENT sid="7" pm="."><plain>Sensitive magnetic resonance imaging (MRI) methods, such as gradient-echo T2* imaging and susceptibility-weighted imaging, are useful for detecting cortical microhemorrhages and cSS. </plain></SENT>
<SENT sid="8" pm="."><plain>Amyloid imaging with amyloid-binding positron emission tomography (PET) ligands, such as Pittsburgh Compound B, can detect CAA, although they cannot discriminate vascular from parenchymal amyloid deposits. </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, cerebrospinal fluid markers may be useful, including levels of Aβ40 for CAA and anti-Aβ antibody for CAA-related inflammation. </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, cSS is closely associated with transient focal neurological episodes (TFNE). </plain></SENT>
<SENT sid="11" pm="."><plain>CAA-related inflammation/angiitis shares pathophysiology with amyloid-related imaging abnormalities (ARIA) induced by Aβ immunotherapies in AD patients. </plain></SENT>
<SENT sid="12" pm="."><plain>This article reviews CAA and CAA-related disorders with respect to their epidemiology, pathology, pathophysiology, clinical features, biomarkers, diagnosis, treatment, risk factors, and future perspectives. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Cerebral amyloid angiopathy</kwd><kwd>Amyloid β-protein</kwd><kwd>Cerebrovascular disorders</kwd><kwd>MRI</kwd><kwd>PET</kwd><kwd>Cerebrospinal fluid</kwd></kwd-group></SecTag><funding-group><award-group><funding-source country="JP">Ministry of Health, Labor and Welfare</funding-source></award-group><award-group><funding-source country="JP">SENSHIN Medical Research Foundation</funding-source></award-group></funding-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="13" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="14" pm="."><plain>Cerebral amyloid angiopathy (CAA) involves cerebrovascular amyloid deposition. </plain></SENT>
<SENT sid="15" pm="."><plain>CAA was described as a cause of normotensive cerebral hemorrhage in older individuals or also described in studies focusing on its close association with Alzheimer's disease (AD). </plain></SENT>
<SENT sid="16" pm="."><plain>The earlier terms to describe CAA include "drüsige Entartung der Arterien und Kapillaren,"1 "aniopathie dyshorique,"2 and "angiopathie congophile."3 The terms "drüsige Entartung" and "angiopathie dyshorique" represent a peculiar form of CAA showing perivascular plaque-like structures. </plain></SENT>
<SENT sid="17" pm="."><plain>Currently, CAA has been used as a general term to describe cerebrovascular amyloid deposition or cerebrovascular amyloidosis.4 </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>CAA is classified into several types according to the amyloid protein involved (Table 1). </plain></SENT>
<SENT sid="19" pm="."><plain>So far, seven amyloid proteins have been reported in CAA including amyloid β-protein (Aβ), cystatin C (ACys), prion protein (APrP), ABri/ADan, transthyretin (ATTR), gelsolin (AGel), and immunoglobulin light chain amyloid (AL); among these, sporadic CAA of the Aβ type is most commonly found in older individuals as well as in patients with AD [see review5]. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>This article reviews sporadic Aβ-type CAA and CAA-related disorders with respect to their epidemiology, pathology, pathophysiology, clinical features, biomarkers, diagnosis, treatment, risk factors, and future perspectives. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="21" pm="."><plain>Epidemiology, pathology, and pathophysiology of CAA </plain></SENT>
</text></title><p><text><SENT sid="22" pm="."><plain>The prevalence of CAA increases with age,6,7 and CAA occurs in approximately half of elderly individuals.6 CAA is commonly observed in AD with a prevalence of about 80%-90%.6,8 CAA-related lobar intracerebral hemorrhage (ICH), identified via a nationwide survey in Japan, increases with age and presents with female predominance.9 </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Pathologically, CAA is observed mainly in the leptomeningeal and cortical vessels of the cerebral lobes and cerebellum. </plain></SENT>
<SENT sid="24" pm="."><plain>For the distribution of CAA, the occipital lobe is preferentially affected,6 whereas CAA is uncommon in the basal ganglia, thalamus, brainstem, and white matter. </plain></SENT>
<SENT sid="25" pm="."><plain>In mild CAA, a small proportion of the leptomeningeal and superficial cortical vessels are affected with amyloid deposition. </plain></SENT>
<SENT sid="26" pm="."><plain>In severe CAA, most small arteries and arterioles are affected with marked amyloid deposition. </plain></SENT>
<SENT sid="27" pm="."><plain>Medium-sized leptomeningeal arteries show amyloid deposition in the outer regions of the media to the adventitia. </plain></SENT>
<SENT sid="28" pm="."><plain>Vessel walls of the small arteries and arterioles are often totally replaced by amyloid deposits, except for the endothelial cells. </plain></SENT>
<SENT sid="29" pm="."><plain>Electron microscopically, amyloid fibrils are focally deposited within the outer basement membrane of the vessels during the initial stage of CAA.10 Later, a large amount of amyloid fibrils accumulate with degeneration of smooth muscle cells of the media (Figure 1A). </plain></SENT>
<SENT sid="30" pm="."><plain>Amyloid deposits in capillaries and, occasionally, in arterioles or small arteries appear to infiltrate the surrounding parenchymal tissue, and accompany dystrophic neurites forming plaque-like structures (drüsige Entartung1/angiopathie dyshorique2). </plain></SENT>
<SENT sid="31" pm="."><plain>Recently, CAA in capillaries has been referred to as "capillary CAA (CAA-Type 1)," to distinguish it from non-capillary CAA (CAA-Type 2).11 Severe CAA is associated with vasculopathies including duplication ("double-barrel" lumen), obliterative intimal changes, hyaline degeneration, microaneurysmal dilatation, and fibrinoid necrosis (Figure 1B, C).12,13,14 These CAA-associated vasculopathies are the pathological basis of CAA-related cerebrovascular disorders. </plain></SENT>
<SENT sid="32" pm="."><plain>In particular, fibrinoid necrosis is closely associated with CAA-related hemorrhage.12,13,14 </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>Aβ is cleaved from the β-amyloid precursor protein (AβPP) by β-secretase and γ-secretase. </plain></SENT>
<SENT sid="34" pm="."><plain>Heterogeneity of the C-terminal is present, and the length of Aβ in senile plaques is mainly 42-43 residues (Aβ42), while that of cerebrovascular Aβ (CAA) is mainly 39-40 residues (Aβ40) (Figure 2).15,16 Recent studies suggest that Aβ in CAA is derived from the brain [see review5]; after release from neurons, Aβ42 easily aggregates and deposits in the brain parenchyma as senile plaques; whereas, Aβ40 does not aggregate as easily as Aβ42, and is transported, through periarterial interstitial fluid drainage pathways, to blood vessels for clearance. </plain></SENT>
<SENT sid="35" pm="."><plain>In this process, Aβ40 aggregates on vascular basement membranes, as first proposed by Weller.17 </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>The pathophysiology of Aβ-type CAA is shown in Figure 3.18 CAA-associated vasculopathies lead to development of hemorrhagic lesions [lobar intracerebral macrohemorrhage, cortical microhemorrhage, and cortical superficial siderosis (cSS)/focal convexity subarachnoid hemorrhage (SAH)], ischemic lesions (cortical infarction and ischemic changes of the white matter), and encephalopathies that include subacute leukoencephalopathy caused by CAA-related inflammation/angiitis (Figure 1). </plain></SENT>
<SENT sid="37" pm="."><plain>In addition, CAA is related to dementia through AD pathology and CAA-related vascular lesions (Figure 1). </plain></SENT>
<SENT sid="38" pm="."><plain>Thus, CAA is related to dementia, stroke, and encephalopathies. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="39" pm="."><plain>Clinical aspects of CAA-related disorders </plain></SENT>
</text></title><sec><title><text><SENT sid="40" pm="."><plain>Clinical features </plain></SENT>
</text></title><sec><title><text><SENT sid="41" pm="."><plain>Intracerebral hemorrhages </plain></SENT>
</text></title><sec><title><text><SENT sid="42" pm="."><plain>Symptomatic lobar intracerebral hemorrhages (ICH) </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>CAA is significantly associated with lobar intracerebral hemorrhage (ICH) (Figure 4A), but not with deep ICH,19 because sporadic Aβ-type CAA is commonly found in the meningeal and cortical vessels of cerebral and cerebellar cortices, and rarely in those of the deep gray matter including basal ganglia, thalamus, and brainstem.6 Using the SMASH-U system (structural lesion, medication, amyloid angiopathy, systemic/other disease, hypertension, undetermined) as a pathogenetic classification system for ICH, CAA-related ICH was noted in 20% of ICH cases in the Helsinki ICH study,20 and 12% of ICH cases in the National Taiwan University Hospital Stroke Registry.21 CAA-related ICH was the second most common cause of ICH following hypertensive angiopathy in these studies.20,21 The incidence of lobar ICH in the elderly has been increasing recently, in which CAA is strongly implicated.22 CAA-related lobar ICH is often multiple and recurrent, and clinical manifestations include motor paresis, disturbance of consciousness, abnormalities in higher brain functions, such as aphasia, visual loss, with headache at the acute stage, and dementia and seizures during chronic stages.9 Headache with meningeal signs is likely caused by subarachnoid hemorrhage (SAH) accompanying lobar ICH.23,24,25 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="44" pm="."><plain>Cortical microhemorrhages </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>Cerebral microhemorrhages (microbleeds) were noted in 16.7%-32% of AD patients, which is higher than in the general population (5%-6%), when examined by gradient-echo T2* MRI,26,27,28,29,30 and in 78% of patients with AD or mild cognitive impairment (MCI) on ultra-high field strength 7T MRI.31 Microhemorrhages were found in 47.4% of patients with pathologically confirmed CAA cases.32 CAA-related microhemorrhages are frequently lobar in distribution (Figure 4B). </plain></SENT>
<SENT sid="46" pm="."><plain>Studies with amyloid positron emission tomography (PET) using 11C-Pittsburgh Compound B (PiB) reported that lobar microhemorrhages are frequently found in PiB-positive healthy subjects as well as patients with AD or mild cognitive impairment (MCI),33 and that microhemorrhages preferentially occur in local regions of concentrated amyloid deposits.34 New hemorrhages occur preferentially at the sites of increased amyloid deposits, suggesting that amyloid imaging may be useful to predict future CAA-related hemorrhages.35 Patients with lobar microhemorrhages are at considerable risk of future symptomatic lobar ICH.36 </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="47" pm="."><plain>Cortical superficial siderosis/focal convexity subarachnoid hemorrhages </plain></SENT>
</text></title><p><text><SENT sid="48" pm="."><plain>CAA is a frequent cause of cSS/focal convexity SAH (Figure 4C), a subtype of nonaneurysmal SAH, in patients over the age of 60 and in those with AD.32,37,38 Notably, cSS is closely associated with microhemorrhages in lobar locations in the general population.39 Moreover, cSS occurs with high prevalence in CAA and is found in 60.5% of pathologically confirmed cases.32,40 Interestingly, cSS tends to occur in individuals with relatively fewer cortical microhemorrhages, suggesting differences in vasculopathic changes between CAA-related microhemorrhages and cSS.41 Furthermore, cSS is associated with an increased future risk of symptomatic lobar ICH.40,42 The prevalence of cSS is higher in patients with AD or cognitive impairment than in the general population.43,44 Interestingly, cSS has been reported to present with transient focal neurological episodes (TFNEs); TFNEs are a clinical marker of cSS and may be caused by cSS through cortical spreading depression or focal seizure activity.45,46,47,48,49 Anti-platelet or anticoagulant therapies based on the misdiagnosis of CAA-related TFNE as a transient ischemic attack may induce CAA-related ICH. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="49" pm="."><plain>White matter disease and cortical infarction </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>CAA-related cerebral hypoperfusion or occlusive small-vessel disease may cause progressive white matter lesions and cortical microinfarcts. </plain></SENT>
<SENT sid="51" pm="."><plain>Patients with CAA-related ICH exhibit occipital dominant white matter hyperintensities (WMHs) on MRI (Figure 4D), compatible with predilection of CAA pathology for posterior brain regions.50 A posterior distribution of WMH on MRI is associated with the presence of CAA pathology.51 Amyloid burden in non-demented CAA subjects correlated with WMH volumes.52 Acute or subacute subclinical ischemic infarcts are common in CAA-related ICH.53,54,55 As a result of the difficulty in detection (see below), CAA as a cause of cortical microinfarcts is underrecognized. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="52" pm="."><plain>Dementia </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>CAA with hemorrhagic/ischemic vascular lesions or AD pathology may be associated with dementia during its clinical course,56 although dementia is found only in a subgroup of patients with CAA-related ICH at the onset of the initial ICH.9,57 Dementia was noted in 74% of individuals with severe CAA at autopsy.56 Moderate-to-very severe CAA is associated with impaired performance in specific cognitive domains, most notably perceptual speed, which is separate from the effect of AD pathology.58 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="54" pm="."><plain>CAA-related inflammation </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>CAA is commonly associated with immune reactions of monocyte/macrophage-lineage cells.59 CAA can be accompanied by marked inflammation (CAA-related inflammation/angiitis), presenting with subacute leukoencephalopathy that is responsive to immunosuppressive therapies.59,60,61,62,63 The clinical symptoms include subacute cognitive impairment or seizure, which are different from those of hemorrhagic stroke in noninflammatory CAA. </plain></SENT>
<SENT sid="56" pm="."><plain>Inflammatory CAA is also characterized by asymmetric T2-hyperintense white matter lesions on MRI.59,60,61,62,63 CAA-related inflammation is associated with an increase in anti-Aβ antibodies in cerebrospinal fluid (CSF).64,65 CAA-related inflammation/angiitis shares pathophysiology with amyloid-related imaging abnormalities (ARIA) induced by Aβ immunotherapies, as discussed below. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="57" pm="."><plain>Biomarkers and diagnosis </plain></SENT>
</text></title><sec><title><text><SENT sid="58" pm="."><plain>Imaging markers </plain></SENT>
</text></title><sec><title><text><SENT sid="59" pm="."><plain>CT/MRI </plain></SENT>
</text></title><p><text><SENT sid="60" pm="."><plain>Cranial CT is an option for macrohemorrhages; however, sensitive MR imaging techniques, such as gradient-echo T2* imaging and susceptibility-weighted imaging, are useful for detecting microhemorrhages and cSS.66 A posterior distribution of WMH is a possible marker of CAA.51 Although acute or subacute cortical or subcortical infarctions can be recognized in CAA on diffusion-weighted images,53 cortical microinfarcts are often undetected on MRI because of their limited size.31 Ultra-high strength clinical MR scanners with a higher spatial resolution may enable their detection.67 CT angiography spot signs, suggestive of an acute bleeding process, are associated with warfarin use and ICH volume in both CAA-related lobar ICH and arteriolosclerotic deep ICH.68 Enlarged perivascular spaces in the centrum semiovale are associated with CAA, suggesting an imaging marker for CAA.69,70,71 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="61" pm="."><plain>Functional imaging </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>Impaired vascular reactivity in response to visual stimulation or a visual task in CAA was reported in studies with transcranial Doppler ultrasound and functional MRI, consistent with greater distribution of CAA in the occipital lobe.72,73,74 </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="63" pm="."><plain>Amyloid PET </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>Amyloid imaging with the PET ligand, PiB, revealed an increase of PiB binding that often shows greater occipital uptake in CAA-related ICH (Figure 5).75,76,77 Microhemorrhages are associated with PiB retention,33,34 and new CAA-related hemorrhages preferentially occur at sites of PiB retention.35 As a frequent occurrence of high PiB uptake in healthy elderly individuals reflects incipient AD, PiB PET has low specificity for CAA; however, a negative PiB scan rules out CAA with excellent sensitivity.78 Amyloid imaging with such PET ligands as PiB cannot discriminate vascular from parenchymal deposition or Aβ from other amyloid proteins; reagents specific for vascular Aβ deposition are favorable candidates for amyloid imaging specific for Aβ-type CAA.79 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="65" pm="."><plain>Biochemical markers </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>A significant decrease in cerebrospinal fluid (CSF) levels of Aβ40 as well as Aβ42 was reported in patients with probable CAA, which suggests trapping of Aβ40 and Aβ42 in the cerebral vasculature. </plain></SENT>
<SENT sid="67" pm="."><plain>Furthermore, CSF levels of total tau and phosphorylated tau are higher in patients with probable CAA than in controls, but lower than in AD.80,81 It was reported that patients with CAA-related ICH exhibit higher plasma levels of Aβ42, Aβ40, and specific Aβ fragments.82 The presence of anti-Aβ autoantibodies in CSF is a marker of CAA-related inflammation.64,65 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="68" pm="."><plain>Diagnosis </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>The Boston criteria were proposed for the diagnosis of CAA-related ICH (Table 2), and high diagnostic accuracy was reported with a small pathologic series.83 As hypertension may cause lobar ICH,23 exclusion of advanced hypertension may increase the specificity of the diagnosis of CAA-related ICH; however, the diagnostic sensitivity is decreased,9 because CAA may coexist with hypertension. </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain>When cSS was incorporated into the classic Boston criteria (the modified Boston criteria) (Table 2), the sensitivity increased from 89.5% to 94.7%, and the specificity was 81.2% for both the classic and modified criteria.32 </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="71" pm="."><plain>Current treatment and prognosis </plain></SENT>
</text></title><p><text><SENT sid="72" pm="."><plain>Currently, no disease-modifying therapies are available for CAA. </plain></SENT>
<SENT sid="73" pm="."><plain>As for neurosurgery for CAA-related ICH, uncontrollable peri- and post-operative hemorrhages have been reported previously; however, recent studies suggest that neurosurgical procedures, especially hematoma evacuation, can be performed more safely than previously expected.84 In our study involving a nationwide survey in Japan,9 neurosurgical procedures were performed without uncontrollable intra-operative or post-operative hemorrhage in 97.1% of patients. </plain></SENT>
<SENT sid="74" pm="."><plain>CAA-related lobar ICH recurred in 31.7% of patients during the average 35.3-month follow-up period. </plain></SENT>
<SENT sid="75" pm="."><plain>The mean interval between ICHs was 11.3 months and the case fatality rate was 12.2% at 1 month and 19.5% at 12 months after initial ICH. </plain></SENT>
<SENT sid="76" pm="."><plain>Subacute leukoencephalopathy associated with CAA-related inflammation or angiitis was reported to respond to immunosuppressive treatment.61,62,63 </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="77" pm="."><plain>Risk factors of CAA and CAA-related disorders </plain></SENT>
</text></title><p><text><SENT sid="78" pm="."><plain>Aging and AD are established risk factors of CAA;5 besides these, genetic and non-genetic risk factors have been reported for CAA and CAA-related disorders. </plain></SENT>
</text></p><sec><title><text><SENT sid="79" pm="."><plain>Genetic risk factors </plain></SENT>
</text></title><sec><title><text><SENT sid="80" pm="."><plain>Apolipoprotein E gene </plain></SENT>
</text></title><p><text><SENT sid="81" pm="."><plain>In addition to hereditary cases of AD/CAA associated with mutations of the AβPP or presenilin genes [see review5], the ApoE gene (ApoE) has been reported to be risk factor for sporadic CAA as well as AD; the ε4 allele for CAA itself, and the ε2 allele for CAA-related ICH85,86,87 and hematoma expansion.88 Carriers of the ApoE ε2 or ε4 allele, particularly, of the ApoE ε2/ε4 genotype were associated with early recurrence of lobar ICH in patients who survived a lobar ICH.89 The ApoE ε4 allele constitutes a risk factor for capillary CAA (CAA-Type 1),11 CAA-related inflammation,63 and brain microhemorrhages.90 Furthermore, ApoE ε2 was overrepresented in patients with cSS.41 The presence of CAA in head injury cases was significantly associated with the ApoE ε4 allele, suggesting an interaction between gene and environment in the development of CAA.91 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="82" pm="."><plain>Other genetic factors </plain></SENT>
</text></title><p><text><SENT sid="83" pm="."><plain>Transforming growth factor (TGF)-β1 is another CAA-related gene reported by more than one research group.92,93 In addition, CAA was reported to be associated with other gene polymorphisms, including the presenilin 1 (PS1), α1-antichymotrypsin (ACT), neprilysin, low-density lipoprotein-receptor related protein (LRP-1), and angiotensin-converting enzyme (ACE) genes.8,94,95,96,97,98,99,100 Furthermore, a CR1 gene polymorphism, reported to increase the risk of AD, was also reported to be associated with increased risk of CAA-ICH and CAA.101 </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="84" pm="."><plain>Non-genetic risk factors </plain></SENT>
</text></title><sec><title><text><SENT sid="85" pm="."><plain>Hypertension </plain></SENT>
</text></title><p><text><SENT sid="86" pm="."><plain>Lowering of blood pressure reduced the risk of CAA-related ICH, suggesting that high blood pressure could be a factor inducing ICH in patients with CAA.102 Hypertension could contribute to progression of CAA-associated vasculopathies, particularly fibrinoid necrosis, leading to the development of CAA-related ICH. </plain></SENT>
<SENT sid="87" pm="."><plain>It was reported that the prevalence of hypertension was significantly higher in autopsy-confirmed CAA patients with ICH than in those without ICH, suggesting a role for hypertension in the development of CAA-related ICH.13 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="88" pm="."><plain>Thrombolytic, anticoagulation, and antiplatelet therapies </plain></SENT>
</text></title><p><text><SENT sid="89" pm="."><plain>There is increasing evidence that CAA could be a risk factor for ICH with thrombolytic therapies for acute myocardial infarction, pulmonary embolism, or ischemic stroke, and for ICH with warfarin therapies.103,104 Thrombolytic or anticoagulation therapies in patients with micorhemorrhages are a potential risk factor for ICH.36,105,106 The ApoE ε2 and ε4 alleles were reported as strong risk factors for lobar warfarin-related ICH; this association was considered to be mediated by the effect of ApoE ε variants on CAA.107 The use of anti-platelet drugs, such as aspirin, is associated with the presence of microhemorrhages, and with strictly lobar microhemorrhages suggestive of CAA.108 In a systematic review of clinical trials with aspirin in AD, ICH was noted in 3.2% of patients in the aspirin group, but in 0% of the control group, suggesting that aspirin use in AD might increase the risk of ICH. </plain></SENT>
<SENT sid="90" pm="."><plain>A possible explanation for the increased risk of ICH could be CAA in AD.109 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="91" pm="."><plain>Anti-amyloid therapies </plain></SENT>
</text></title><p><text><SENT sid="92" pm="."><plain>Clinical and experimental studies of Aβ immunotherapies for AD have reported CAA-related complications. </plain></SENT>
<SENT sid="93" pm="."><plain>In clinical trials with Aβ42 immunization for AD (AN1792, Elan), immunized patients showed a significantly greater frequency of CAA, cortical microhemorrhages, and microvascular lesions than unimmunized AD controls, although the longest living had a virtually complete absence of both plaques and CAA.110 A CAA-related macrohemorrhage was reported in an AD patient in phase 2a of AN1792.111 The findings suggest that Aβ immunization resulted in solubilization of Aβ42 in plaques, which migrates out of the brain parenchyma via perivascular interstitial drainage pathways, causing an increase in CAA and CAA-related hemorrhages.110 Menigoencephalitis occurred in 6% of patients treated in the AN1792 trial,111 and perivascular infiltration of lymphocytes was observed around vessels with CAA.112 Furthermore, in a phase 2 trial of bapineuzumab, a humanized monoclonal anti-Aβ antibody, amyloid-related imaging abnormalities (ARIA) were reported: vasogenic edema and sulcal effusions (ARIA-E) in 17%, and microhemorrhages and hemosiderin deposits (ARIA-H) in 47% of the patients with ARIA-E,113 suggesting that Aβ immunotherapy resulted in changes in permeability and disruption of CAA-affected vessels. </plain></SENT>
<SENT sid="94" pm="."><plain>Vasogenic edema was noted in 2 of 2,762 patients with AD at the baseline of the clinical trial; findings were compatible with CAA-related inflammation.114 As discussed above, CAA-related inflammation is associated with the presence of anti-Aβ autoantibodies in CSF.64,65 Further studies are required to elucidate the link between Aβ immunotherapy-induced ARIA and CAA-related inflammation. </plain></SENT>
</text></p></sec></sec></sec><SecTag type="DISCUSS,CONCL"><sec><title><text><SENT sid="95" pm="."><plain>Future perspectives of prediction, prevention, and therapies for CAA and CAA-related disorders </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>Biomarker findings and risk factors for CAA and CAA-related disorders are summarized in Table 3. </plain></SENT>
<SENT sid="97" pm="."><plain>A number of studies indicate that the presence of one or more biomarkers plus one or more risk factors suggest the future development of CAA-related disorders. </plain></SENT>
<SENT sid="98" pm="."><plain>Further prospective studies will establish methods for prediction of CAA-related disorders. </plain></SENT>
<SENT sid="99" pm="."><plain>To develop preventive and therapeutic methods for CAA and CAA-related disorders, their molecular pathogenesis needs to be further elucidated. </plain></SENT>
<SENT sid="100" pm="."><plain>The molecular pathogenesis of Aβ deposition in cerebral blood vessels is discussed in detail elsewhere [see review5]. </plain></SENT>
</text></p><p><text><SENT sid="101" pm="."><plain>CAA is not necessarily associated with CAA-related disorders. </plain></SENT>
<SENT sid="102" pm="."><plain>The pathogenesis of CAA-related disorders consists of two steps: (1) cerebrovascular amyloid deposition and (2) vascular injury including disruption, occlusion, and permeability changes. </plain></SENT>
<SENT sid="103" pm="."><plain>The cerebrovascular amyloid deposition (Step 1) is the primary target of prevention and therapy. </plain></SENT>
<SENT sid="104" pm="."><plain>Anti-amyloid therapies for CAA are under development including ponezumab, a humanized monoclonal antibody that binds specifically to the carboxyl terminus of Aβ40.115 Ponezumab was originally developed for AD immunotherapy, and an acceptable safety profile has been suggested for ponezumab in clinical trials for AD.116,117,118 Currently, ponezumab has been applied to CAA. </plain></SENT>
<SENT sid="105" pm="."><plain>A phase 2, randomized, double-blind, placebo-controlled trial is ongoing to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponezumab (PF-04360365) in adult patients with probable CAA-related hemorrhages (NCT01821118).119 </plain></SENT>
</text></p><p><text><SENT sid="106" pm="."><plain>Vascular injury secondary to cerebrovascular amyloid deposition (Step 2) is an important target for prevention of CAA-related disorders. </plain></SENT>
<SENT sid="107" pm="."><plain>Risk factors and pathogenic mechanisms underlying vascular injury leading to CAA-related hemorrhages are discussed below. </plain></SENT>
<SENT sid="108" pm="."><plain>For CAA-related hemorrhages, several non-genetic risk factors have been reported and it is recommended to avoid them. </plain></SENT>
<SENT sid="109" pm="."><plain>These include thrombolytic, anticoagulation, and anti-platelet therapies, hypertension, and minor head trauma in patients with positive biomarkers of CAA and CAA-related disorders (Table 3). </plain></SENT>
<SENT sid="110" pm="."><plain>Pathogenic mechanisms underlying the damage and rupture of CAA-affected vessels remain to be determined. </plain></SENT>
<SENT sid="111" pm="."><plain>Pathologically, severe CAA is associated with vasculopathies including loss of smooth muscle cells, duplication ("double-barrel" lumen), obliterative intimal changes, hyaline degeneration, microaneurysmal dilatation, and fibrinoid necrosis of the vessel walls (Figure 1).12,13,14 Of these, fibrinoid necrosis, in particular, is closely linked to CAA-related hemorrhage.12,13,14 In addition, even in cases without obvious inflammation or angiitis, CAA-affected vessels are associated with an increase in and activation of monocyte/macrophage lineage cells representing immune reactions against vascular amyloid deposition,59 which would damage the vessel walls. </plain></SENT>
<SENT sid="112" pm="."><plain>Aβ deposits in blood vessel walls may trigger release of inflammatory components, activation of the complement system, oxidative stress, alterations in blood brain barrier permeability, formation of ion-like channels, and cell toxicity.120 The involvement of matrix metalloproteinases in the degradation of extracellular matrix proteins was suggested in an experimental model and in human brains exhibiting CAA-related ICH.121,122 Soluble Aβ oligomers, which are more neurotoxic than insoluble Aβ fibrils, may damage vessel walls affected with CAA. </plain></SENT>
<SENT sid="113" pm="."><plain>There is increased evidence that ApoE ε2 is associated with CAA-related ICH and vessel fragility;87,88,123,124 however, ApoE-related pathogenic mechanisms remain to be elucidated. </plain></SENT>
<SENT sid="114" pm="."><plain>Future preventive/therapeutic strategies for CAA-related hemorrhages should include protection of vessel walls against these factors, as well as the development of anti-amyloid therapies for CAA. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="115" pm="."><plain>The study was supported in part by a grant from the Amyloidosis Research Committee from the Ministry of Health, Labor and Welfare, Japan, and by the SENSHIN Medical Research Foundation, Japan. </plain></SENT>
<SENT sid="116" pm="."><plain>The author is grateful to Ms. </plain></SENT>
<SENT sid="117" pm="."><plain>Etsuko Tsujiguchi for her excellent secretarial work. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><SecTag type="COMP_INT"><fn fn-type="conflict"><p><text><SENT sid="118" pm="."><plain>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="119" pm="."><plain>1ScholzWStudien zur Pathologie der Hirngefäße II. </plain></SENT>
<SENT sid="120" pm="."><plain>Die drusige Entartung der Hirnarterien und KapillarenZ ges Neurol Psychiat1938162694715 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="121" pm="."><plain>2SurbekBL'angiopathie dyshorique (Morel) de l'écorce cérébraleActa Neuropathol19611168197 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="122" pm="."><plain>3PantelakisSUn type particulier d'angiopathie sénile du système nerveux central: l'angiopathice congophile. </plain></SENT>
<SENT sid="123" pm="."><plain>Topographie et fréquenceMschr Psychiatr Neurol1954128219256 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="124" pm="."><plain>4VintersHVCerebral amyloid angiopathy. </plain></SENT>
<SENT sid="125" pm="."><plain>A critical reviewStroke1987183113243551211 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="126" pm="."><plain>5YamadaMNaikiHCerebral amyloid angiopathyProg Mol Biol Transl Sci201251417822482447 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="127" pm="."><plain>6YamadaMTsukagoshiHOtomoEHayakawaMCerebral amyloid angiopathy in the agedJ Neurol19872343713763655840 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="128" pm="."><plain>7MasudaJTanakaKUedaKOmaeTAutopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, JapanStroke1988192052103344537 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="129" pm="."><plain>8YamadaMRisk factors for cerebral amyloid angiopathy in the elderlyAnn N Y Acad Sci2002977374412480732 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="130" pm="."><plain>9HirohataMYoshitaMIshidaCIkedaSITamaokaAKuzuharaSClinical features of non-hypertensive lobar intracerebral hemorrhage related to cerebral amyloid angiopathyEur J Neurol20101782382920158508 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="131" pm="."><plain>10YamaguchiHYamazakiTLemereCAFroschMPSelkoeDJBeta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. </plain></SENT>
<SENT sid="132" pm="."><plain>An immunoelectron microscopic studyAm J Pathol19921412492591632466 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="133" pm="."><plain>11ThalDRGhebremedhinERubUYamaguchiHDel TrediciKBraakHTwo types of sporadic cerebral amyloid angiopathyJ Neuropathol Exp Neurol20026128229311895043 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="134" pm="."><plain>12MandyburTICerebral amyloid angiopathy: the vascular pathology and complicationsJ Neuropathol Exp Neurol19864579903941328 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="135" pm="."><plain>13VonsattelJPMyersRHHedley-WhyteETRopperAHBirdEDRichardsonEPJrCerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological studyAnn Neurol1991306376491763890 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="136" pm="."><plain>14MaedaAYamadaMItohYOtomoEHayakawaMMiyatakeTComputer-assisted three-dimensional image analysis of cerebral amyloid angiopathyStroke199324185718648248968 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="137" pm="."><plain>15PrelliFCastanoEGlennerGGFrangioneBDifferences between vascular and plaque core amyloid in Alzheimer's diseaseJ Neurochem1988516486513292706 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="138" pm="."><plain>16SuzukiNIwatsuboTOdakaAIshibashiYKitadaCIharaYHigh tissue content of soluble β1-40 is linked to cerebral amyloid angiopathyAm J Pathol19941454524608053502 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="139" pm="."><plain>17WellerROMasseyANewmanTAHutchingsMKuoYMRoherAECerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's diseaseAm J Pathol19981537257339736023 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="140" pm="."><plain>18YamadaMPredicting cerebral amyloid angiopathy-related intracerebral hemorrhages and other cerebrovascular disorders in Alzheimer's diseaseFront Neurol201236422539931 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="141" pm="."><plain>19SamarasekeraNSmithCAl-Shahi SalmanRThe association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysisJ Neurol Neurosurg Psychiatry20128327528122056966 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="142" pm="."><plain>20MeretojaAStrbianDPutaalaJCurtzeSHaapaniemiEMustanojaSSMASH-U: a proposal for etiologic classification of intracerebral hemorrhageStroke2012432592259722858729 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="143" pm="."><plain>21YehSJTangSCTsaiLKJengJSPathogenetical subtypes of recurrent intracerebral hemorrhage: designations by SMASH-U classification systemStroke2014452636264225052320 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="144" pm="."><plain>22BéjotYCordonnierCDurierJAboa-EbouléCRouaudOGiroudMIntracerebral haemorrhage profiles are changing: results from the Dijon population-based studyBrain201313665866423378220 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="145" pm="."><plain>23ItohYYamadaMHayakawaMOtomoEMiyatakeTCerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderlyJ Neurol Sci19931161351418336159 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="146" pm="."><plain>24YamadaMItohYOtomoEHayakawaMMiyatakeTSubarachnoid haemorrhage in the elderly: a necropsy study of the association with cerebral amyloid angiopathyJ Neurol Neurosurg Psychiatry1993565435478505648 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="147" pm="."><plain>25OhshimaTEndoTNukuiHIkedaSAllsopDOnayaTCerebral amyloid angiopathy as a cause of subarachnoid hemorrhageStroke1990214804832309274 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="148" pm="."><plain>26HanyuHTanakaYShimizuSTakasakiMAbeKCerebral microbleeds in Alzheimer's diseaseJ Neurol20032501496149714673587 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="149" pm="."><plain>27Nakata-KudoYMizunoTYamadaKShigaKYoshikawaKMoriSMicrobleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular diseaseDement Geriatr Cogn Disord20062281416645275 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="150" pm="."><plain>28CordonnierCvan der FlierWMSluimerJDLeysDBark hofFScheltensPPrevalence and severity of microbleeds in a memory clinic settingNeurology2006661356136016682667 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="151" pm="."><plain>29CordonnierCAl-Shahi SalmanRWardlawJSpontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reportingBrain20071301988200317322562 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="152" pm="."><plain>30PettersenJASathiyamoorthyGGaoFQSzilagyiGNadkarniNKSt George-HyslopPMicrobleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia studyArch Neurol20086579079518541799 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="153" pm="."><plain>31BrundelMHeringaSMde BresserJKoekHLZwanenburgJJJaap KappelleLHigh prevalence of cerebral microbleeds at 7Tesla MRI in patients with early Alzheimer's diseaseJ Alzheimers Dis20123125926322531417 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="154" pm="."><plain>32LinnJHalpinADemaerelPRuhlandJGieseADDichgansMPrevalence of superficial siderosis in patients with cerebral amyloid angiopathyNeurology2010741346135020421578 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="155" pm="."><plain>33YatesPASirisriroRVillemagneVLFarquharsonSMastersCLRoweCCCerebral microhemorrhage and brain β-amyloid in aging and Alzheimer diseaseNeurology201177485421700585 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="156" pm="."><plain>34DierksenGASkehanMEKhanMAJengJNandigamRNBeckerJASpatial relation between microbleeds and amyloid deposits in amyloid angiopathyAnn Neurol20106854554820865701 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="157" pm="."><plain>35GurolMEDierksenGBetenskyRGidicsinCHalpinABeckerAPredicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathyNeurology20127932032622786597 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="158" pm="."><plain>36van EttenESAurielEHaleyKEAyresAMVashkevichASchwabKMIncidence of symptomatic hemorrhage in patients with lobar microbleedsStroke2014452280228524947286 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="159" pm="."><plain>37FeldmanHHMaiaLFMackenzieIRForsterBBMartzkeJWoolfendenASuperficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer diseaseStroke2008392894289718635858 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="160" pm="."><plain>38KumarSGoddeauRPJrSelimMHThomasASchlaugGAlhazzaniAAtraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologiesNeurology20107489389920231664 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="161" pm="."><plain>39VernooijMWIkramMAHofmanAKrestinGPBretelerMMvan der LugtASuperficial siderosis in the general populationNeurology20097320220519620607 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="162" pm="."><plain>40CharidimouAPeetersAPJägerRFoxZVandermeerenYLalouxPCortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathyNeurology2013811666167324107862 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="163" pm="."><plain>41ShoamaneshAMartinez-RamirezSOliveira-FilhoJReijmerYFalconeGJAyresAInterrelationship of superficial siderosis and microbleeds in cerebral amyloid angiopathyNeurology2014831838184325320098 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="164" pm="."><plain>42LinnJWollenweberFALummelNBochmannKPfefferkornTGschwendtnerASuperficial siderosis is a warning sign for future intracranial hemorrhageJ Neurol201326017618122820723 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="165" pm="."><plain>43WollenweberFABuergerKMuellerCErtl-WagnerBMalikRDichgansMPrevalence of cortical superficial siderosis in patients with cognitive impairmentJ Neurol201426127728224221645 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="166" pm="."><plain>44ZonneveldHIGoosJDWattjesMPPrinsNDScheltensPvan der FlierWMPrevalence of cortical superficial siderosis in a memory clinic populationNeurology20148269870424477113 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="167" pm="."><plain>45IzenbergAAvivRIDemaerschalkBMDodickDWHopyanJBlackSECrescendo transient aura attacks: a transient ischemic attack mimic caused by focal subarachnoid hemorrhageStroke2009403725372919893001 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="168" pm="."><plain>46BeitzkeMGattringerTEnzingerCWagnerGNiederkornKFazekasFClinical presentation, etiology, and long-term prognosis in patients with nontraumatic convexal subarachnoid hemorrhageStroke2011423055306021921284 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="169" pm="."><plain>47CharidimouAPeetersAFoxZGregoireSMVandermeerenYLalouxPSpectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysisStroke2012432324233022798323 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="170" pm="."><plain>48ApoilMCogezJDubucLBatailleMde la SayetteVTouzéEFocal cortical subarachnoid hemorrhage revealed by recurrent paresthesias: a clinico-radiological syndrome strongly associated with cerebral amyloid angiopathyCerebrovasc Dis20133613914424029731 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="171" pm="."><plain>49CharidimouABaronJCWerringDJTransient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAsInt J Stroke2013810510823336261 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="172" pm="."><plain>50ZhuYCChabriatHGodinODufouilCRosandJGreenbergSMDistribution of white matter hyperintensity in cerebral hemorrhage and healthy agingJ Neurol201225953053621877206 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="173" pm="."><plain>51ThanprasertsukSMartinez-RamirezSPontes-NetoOMNiJAyresAReedAPosterior white matter disease distribution as a predictor of amyloid angiopathyNeurology20148379480025063759 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="174" pm="."><plain>52GurolMEViswanathanAGidicsinCHeddenTMartinez-RamirezSDumasACerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging studyAnn Neurol20137352953623424091 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="175" pm="."><plain>53KimberlyWTGilsonARostNSRosandJViswanathanASmithEESilent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathyNeurology2009721230123519349602 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="176" pm="."><plain>54GregoireSMCharidimouAGadapaNDolanEAntounNPeetersAAcute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging studyBrain20111342376238621841203 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="177" pm="."><plain>55VallatWMaundrellALeydenJKleinigTJCerebral amyloid angiopathy causing cortical microinfarctionJ Clin Neurosci2013201802180423871452 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="178" pm="."><plain>56YamadaMItohYSuematsuNOtomoEMatsushitaMVascular variant of Alzheimer's disease characterized by severe plaque-like beta protein angiopathyDement Geriatr Cogn Disord199781631689137894 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="179" pm="."><plain>57CordonnierCLeysDDumontFDeramecourtVBordetRPasquierFWhat are the causes of pre-existing dementia in patients with intracerebral haemorrhages?Brain20101333281328920852266 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="180" pm="."><plain>58ArvanitakisZLeurgansSEWangZWilsonRSBennettDASchneiderJACerebral amyloid angiopathy pathology and cognitive domains in older personsAnn Neurol20116932032721387377 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="181" pm="."><plain>59YamadaMItohYShintakuMKawamuraJJenssonOThorsteinssonLImmune reactions associated with cerebral amyloid angiopathyStroke199627115511628685920 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="182" pm="."><plain>60OhUGuptaRKrakauerJWKhandjiAGChinSSElkindMSReversible leukoencephalopathy associated with cerebral amyloid angiopathyNeurology20046249449714872042 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="183" pm="."><plain>61EngJAFroschMPChoiKRebeckGWGreenbergSMClinical manifestations of cerebral amyloid angiopathy-related inflammationAnn Neurol20045525025614755729 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="184" pm="."><plain>62ScoldingNJJosephFKirbyPAMazantiIGrayFMikolJAβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathyBrain200512850051515659428 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="185" pm="."><plain>63KinnecomCLevMHWendellLSmithEERosandJFroschMPCourse of cerebral amyloid angiopathy-related inflammationNeurology2007681411141617452586 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="186" pm="."><plain>64DiFrancescoJCBrioschiMBrighinaLRuffmannCSaracchiECostantinoGAnti-Aβ autoantibodies in the CSF of a patient with CAA-related inflammation: a case reportNeurology20117684284421357837 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="187" pm="."><plain>65PiazzaFGreenbergSMSavoiardoMGardinettiMChiappariniLRaicherIAnti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapiesAnn Neurol20137344945823625526 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="188" pm="."><plain>66NandigamRNViswanathanADelgadoPSkehanMESmithEERosandJMR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strengthAJNR Am J Neuroradiol20093033834319001544 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="189" pm="."><plain>67IiYMaedaMKidaHMatsuoKShindoATaniguchiAIn vivo detection of cortical microinfarcts on ultrahigh-field MRIJ Neuroimaging201323283222607584 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="190" pm="."><plain>68RadmaneshFFalconeGJAndersonCDBatteyTWAyresAMVashkevichARisk factors for computed tomography angiography spot sign in deep and lobar intracerebral hemorrhage are sharedStroke2014451833183524876264 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="191" pm="."><plain>69CharidimouAMeegahageRFoxZPeetersAVandermeerenYLalouxPEnlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort studyJ Neurol Neurosurg Psychiatry20138462462923412074 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="192" pm="."><plain>70CharidimouAJaunmuktaneZBaronJCBurnellMVarletPPeetersAWhite matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy?Neurology201482576224285616 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="193" pm="."><plain>71CharidimouAJägerRHPeetersAVandermeerenYLalouxPBaronJCWhite matter perivascular spaces are related to cortical superficial siderosis in cerebral amyloid angiopathyStroke2014452930293525116879 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="194" pm="."><plain>72SmithEEVijayappaMLimaFDelgadoPWendellLRosandJImpaired visual evoked flow velocity response in cerebral amyloid angiopathyNeurology2008711424143018955685 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="195" pm="."><plain>73DumasADierksenGAGurolMEHalpinAMartinez-RamirezSSchwabKFunctional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathyAnn Neurol201272768122829269 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="196" pm="."><plain>74PecaSMcCrearyCRDonaldsonEKumarpillaiGShobhaNSanchezKNeurovascular decoupling is associated with severity of cerebral amyloid angiopathyNeurology2013811659166524097810 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="197" pm="."><plain>75JohnsonKAGregasMBeckerJAKinnecomCSalatDHMoranEKImaging of amyloid burden and distribution in cerebral amyloid angiopathyAnn Neurol20076222923417683091 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="198" pm="."><plain>76BacskaiBJFroschMPFreemanSHRaymondSBAugustinackJCJohnsonKAMolecular imaging with Pittsburgh Compound B confirmed at autopsy: a case reportArch Neurol20076443143417353389 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="199" pm="."><plain>77LyJVDonnanGAVillemagneVLZavalaJAMaHO'KeefeG11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhageNeurology20107448749320142615 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="200" pm="."><plain>78BaronJCFaridKDolanETurcGMarrapuSTO'BrienEDiagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhageJ Cereb Blood Flow Metab20143475375824619277 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="201" pm="."><plain>79RutgersKSvan RemoortereAvan BuchemMAVerripsCTGreenbergSMBacskaiBJDifferential recognition of vascular and parenchymal beta amyloid depositionNeurobiol Aging2011321774178320015576 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="202" pm="."><plain>80VerbeekMMKremerBPRikkertMOVan DomburgPHSkehanMEGreenbergSMCerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathyAnn Neurol20096624524919743453 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="203" pm="."><plain>81RenardDCastelnovoGWacongneALe FlochAThouvenotEMasJInterest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteriaJ Neurol20122592429243322576334 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="204" pm="."><plain>82Hernandez-GuillamonMDelgadoPPenalbaARodriguez-LunaDMolinaCARoviraAPlasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic strokeNeurodegener Dis20121032032322261638 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="205" pm="."><plain>83KnudsenKARosandJKarlukDGreenbergSMClinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteriaNeurology20015653753911222803 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="206" pm="."><plain>84GreeneGMGoderskyJCBillerJHartMNAdamsHPJrSurgical experience with cerebral amyloid angiopathyStroke199021154515492237947 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="207" pm="."><plain>85GreenbergSMRebeckGWVonsattelJPGomez-IslaTHymanBTApolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathyAnn Neurol1995382542597654074 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="208" pm="."><plain>86PremkumarDRCohenDLHederaPFriedlandRPKalariaRNApolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s diseaseAm J Pathol1996148208320958669492 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="209" pm="."><plain>87NicollJABurnettCLoveSGrahamDIDewarDIronsideJWHigh frequency of apolipoprotein E ε2 allele in hemorrhage due to cerebral amyloid angiopathyAnn Neurol1997417167219189032 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="210" pm="."><plain>88BrouwersHBBiffiAMcNamaraKAAyresAMValantVSchwabKApolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhageStroke2012432120212522621984 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="211" pm="."><plain>89O'DonnellHCRosandJKnudsenKAFurieKLSegalAZChiuRIApolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhageN Engl J Med200034224024510648765 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="212" pm="."><plain>90MaxwellSSJacksonCAPaternosterLCordonnierCThijsVAl-Shahi SalmanRGenetic associations with brain microbleeds: systematic review and meta-analysesNeurology20117715816721715706 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="213" pm="."><plain>91LeclercqPDMurrayLSSmithCGrahamDINicollJAGentlemanSMCerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotypeJ Neurol Neurosurg Psychiatry20057622923315654038 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="214" pm="."><plain>92HamaguchiTOkinoSSodeyamaNItohYTakahashiAOtomoEAssociation of a polymorphism of the transforming growth factor-β1 gene with cerebral amyloid angiopathyJ Neurol Neurosurg Psychiatry20057669669915834029 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="215" pm="."><plain>93PeilaRYucesoyBWhiteLRJohnsonVKashonMLWuKA TGF-β1 polymorphism association with dementia and neuropathologies: the HAASNeurobiol Aging2007281367137316904244 </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="216" pm="."><plain>94YamadaMCerebral amyloid angiopathy and gene polymorphismsJ Neurol Sci2004226414415537517 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="217" pm="."><plain>95YamadaMSodeyamaNItohYSuematsuNOtomoEMatsushitaMAssociation of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderlyStroke199728221922219368568 </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="218" pm="."><plain>96YamadaMSodeyamaNItohYSuematsuNOtomoEMatsushitaMAssociation of α1-antichymotrypsin polymorphism with cerebral amyloid angiopathyAnn Neurol1998441291319667601 </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="219" pm="."><plain>97YamadaMSodeyamaNItohYTakahashiAOtomoEMatsushitaMAssociation of neprilysin polymorphism with cerebral amyloid angiopathyJ Neurol Neurosurg Psychiatry20037474975112754344 </plain></SENT>
</text></ref><ref id="B98"><text><SENT sid="220" pm="."><plain>98ChristoforidisMSchoberRKrohnKGenetic-morphologic association study: association between the low density lipoprotein-receptor related protein (LRP) and cerebral amyloid angiopathyNeuropathol Appl Neurobiol200531111915634227 </plain></SENT>
</text></ref><ref id="B99"><text><SENT sid="221" pm="."><plain>99Domingues-MontanariSHernandez-GuillamonMFernandez-CadenasIMendiorozMBoadaMMunueraJACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathyNeurobiol Aging20113255120381197 </plain></SENT>
</text></ref><ref id="B100"><text><SENT sid="222" pm="."><plain>100ThalDRPapassotiropoulosASaidoTCGriffinWSMrakREKolschHCapillary cerebral amyloid angiopathy identifies a distinct APOE ε4-associated subtype of sporadic Alzheimer's diseaseActa Neuropathol201012016918320535486 </plain></SENT>
</text></ref><ref id="B101"><text><SENT sid="223" pm="."><plain>101BiffiAShulmanJMJagiellaJMCortelliniLAyresAMSchwabKGenetic variation at CR1 increases risk of cerebral amyloid angiopathyNeurology20127833434122262751 </plain></SENT>
</text></ref><ref id="B102"><text><SENT sid="224" pm="."><plain>102ArimaHTzourioCAndersonCWoodwardMBousserMGMacMahonSEffects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trialStroke20104139439620044530 </plain></SENT>
</text></ref><ref id="B103"><text><SENT sid="225" pm="."><plain>103RosandJHylekEMO'DonnellHCGreenbergSMWarfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic studyNeurology20005594795111061249 </plain></SENT>
</text></ref><ref id="B104"><text><SENT sid="226" pm="."><plain>104McCarronMONicollJACerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhageLancet Neurol2004348449215261609 </plain></SENT>
</text></ref><ref id="B105"><text><SENT sid="227" pm="."><plain>105CharidimouAKakarPFoxZWerringDJCerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysisJ Neurol Neurosurg Psychiatry20138427728023024352 </plain></SENT>
</text></ref><ref id="B106"><text><SENT sid="228" pm="."><plain>106CharidimouAShakeshaftCWerringDJCerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage riskFront Neurol2012313323015806 </plain></SENT>
</text></ref><ref id="B107"><text><SENT sid="229" pm="."><plain>107FalconeGJRadmaneshFBrouwersHBBatteyTWDevanWJValantVAPOE ε variants increase risk of warfarin-related intracerebral hemorrhageNeurology2014831139114625150286 </plain></SENT>
</text></ref><ref id="B108"><text><SENT sid="230" pm="."><plain>108VernooijMWHaagMDvan der LugtAHofmanAKrestinGPStrickerBHUse of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan StudyArch Neurol20096671472019364926 </plain></SENT>
</text></ref><ref id="B109"><text><SENT sid="231" pm="."><plain>109ThoonsenHRichardEBenthamPGrayRvan GelovenNDe HaanRJAspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern?Stroke2010412690269220930165 </plain></SENT>
</text></ref><ref id="B110"><text><SENT sid="232" pm="."><plain>110BocheDZotovaEWellerROLoveSNealJWPickeringRMConsequence of Aβ immunization on the vasculature of human Alzheimer's disease brainBrain20081313299329918953056 </plain></SENT>
</text></ref><ref id="B111"><text><SENT sid="233" pm="."><plain>111OrgogozoJMGilmanSDartiguesJFLaurentBPuelMKirbyLCSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunizationNeurology200361465412847155 </plain></SENT>
</text></ref><ref id="B112"><text><SENT sid="234" pm="."><plain>112NicollJAWilkinsonDHolmesCSteartPMarkhamHWellerRONeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case reportNat Med2003944845212640446 </plain></SENT>
</text></ref><ref id="B113"><text><SENT sid="235" pm="."><plain>113SperlingRSallowaySBrooksDJTampieriDBarakosJFoxNCAmyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisLancet Neurol20121124124922305802 </plain></SENT>
</text></ref><ref id="B114"><text><SENT sid="236" pm="."><plain>114CarlsonCEstergardWOhJSuhyJJackCRSiemersEPrevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumabAlzheimers Dement2011739640121784350 </plain></SENT>
</text></ref><ref id="B115"><text><SENT sid="237" pm="."><plain>115La PorteSLBolliniSSLanzTAAbdicheYNRusnakASHoWHStructural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's diseaseJ Mol Biol201242152553622197375 </plain></SENT>
</text></ref><ref id="B116"><text><SENT sid="238" pm="."><plain>116MiyoshiIFujimotoYYamadaMAbeSZhaoQCronenbergerCSafety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation studyInt J Clin Pharmacol Ther20135191192324131736 </plain></SENT>
</text></ref><ref id="B117"><text><SENT sid="239" pm="."><plain>117BursteinAHZhaoQRossJStyrenSLandenJWMaWWSafety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer diseaseClin Neuropharmacol20133681323334069 </plain></SENT>
</text></ref><ref id="B118"><text><SENT sid="240" pm="."><plain>118LandenJWZhaoQCohenSBorrieMWoodwardMBillingCBSafety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation studyClin Neuropharmacol201336142323334070 </plain></SENT>
</text></ref><ref id="B119"><text><SENT sid="241" pm="."><plain>119ClinicalTrials.gov2014Accessed on November 7<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link> </plain></SENT>
</text></ref><ref id="B120"><text><SENT sid="242" pm="."><plain>120ReveszTHoltonJLLashleyTPlantGFrangioneBRostagnoAGenetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathiesActa Neuropathol200911811513019225789 </plain></SENT>
</text></ref><ref id="B121"><text><SENT sid="243" pm="."><plain>121Hernandez-GuillamonMMartinez-SaezEDelgadoPDomingues-MontanariSBoadaCPenalbaAMMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic strokeBrain Pathol20122213314121707819 </plain></SENT>
</text></ref><ref id="B122"><text><SENT sid="244" pm="."><plain>122LeeJMYinKHsinIChenSFryerJDHoltzmanDMMatrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhageJ Neurol Sci2005229-23024925415760647 </plain></SENT>
</text></ref><ref id="B123"><text><SENT sid="245" pm="."><plain>123McCarronMONicollJAStewartJIronsideJWMannDMLoveSThe apolipoprotein E ε2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhageJ Neuropathol Exp Neurol19995871171810411341 </plain></SENT>
</text></ref><ref id="B124"><text><SENT sid="246" pm="."><plain>124BiffiAAndersonCDJagiellaJMSchmidtHKisselaBHansenBMAPOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association studyLancet Neurol20111070270921741316 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="247" pm="."><plain>CAA and CAA-associated vasculopathies. </plain></SENT>
<SENT sid="248" pm="."><plain>Massive amyloid deposition of amyloid fibrils with degeneration of smooth muscle cells in the media (A). </plain></SENT>
<SENT sid="249" pm="."><plain>Microaneurysmal dilatation (arrow) with fibrinoid necrosis (*) (B). </plain></SENT>
<SENT sid="250" pm="."><plain>Thickening of the intima (arrow) and double barreling of vascular walls (arrowheads) (C). </plain></SENT>
<SENT sid="251" pm="."><plain>(A, electron micrograph, bar=1 µm; B, Congo red, original magnification 110×; C, Congo red, original magnification 170×). </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-g001"/></fig></SecTag><SecTag type="FIG"><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="252" pm="."><plain>Immunohistochemistry of adjacent brain sections with antibodies to Aβ40 (A) and Aβ42 (B). </plain></SENT>
<SENT sid="253" pm="."><plain>Positive immunoreactivity to Aβ40 is mainly observed in vessel walls (CAA) (A), whereas Aβ42 immunoreactivity is mainly observed in the brain parenchyma (senile plaques) (B). </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-g002"/></fig></SecTag><SecTag type="FIG"><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="254" pm="."><plain>Pathophysiology of cerebral amyloid angiopathy (CAA)-related disorders. </plain></SENT>
<SENT sid="255" pm="."><plain>Aβ shows parenchymal (senile plaques) or vascular deposition (CAA) depending on dominance of Aβ42 or Aβ40, respectively. </plain></SENT>
<SENT sid="256" pm="."><plain>CAA is related to stroke and dementia. </plain></SENT>
<SENT sid="257" pm="."><plain>Hx, hemorrhagic events; Ix, ischemic events; IR, immune reaction against Aβ. </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-g003"/></fig></SecTag><SecTag type="FIG"><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="258" pm="."><plain>Imaging findings of CAA-related hemorrhages and white matter lesions. </plain></SENT>
<SENT sid="259" pm="."><plain>Fresh (arrow) and old (arrowhead) lobar macrohemorrhages in the frontal lobes on CT (A). </plain></SENT>
<SENT sid="260" pm="."><plain>Cortical microhemorrhages with lobar distribution (B) and focal subarachnoid hemorrhages (superficial siderosis) (C) on gradient echo T2*-weighted MRI. </plain></SENT>
<SENT sid="261" pm="."><plain>Posterior distribution of white matter hyperintensities (arrows on T2-weighted MRI) (D). </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-g004"/></fig></SecTag><SecTag type="FIG"><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><p><text><SENT sid="262" pm="."><plain>Amyloid positron emission tomography (PET) using 11C-Pittsburgh Compound B (PiB) (A) with gradient echo T2*-weighted MRI (B) in a non-demented patient with multiple CAA-related intracerebral hemorrhages and disseminated cortical superficial siderosis. </plain></SENT>
<SENT sid="263" pm="."><plain>The left parietal region with an old intracerebral hemorrhage shows a relative scarcity of PiB uptake. </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-g005"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="264" pm="."><plain>Classification of cerebral amyloid angiopathy (CAA) </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-i001"/></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="265" pm="."><plain>Classic83* and modified Boston criteria32† for diagnosis of CAA-related hemorrhage </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-i002"/><table-wrap-foot><fn><p><sup>*</sup>Criteria established by the Boston Cerebral Amyloid Angiopathy Group: Steven M. Greenberg, MD, PhD, Daniel S. Kanter, MD, Carlos S. Kase, MD, and Michael S. Pessin, MD.</p><p><sup>†</sup>The modified criteria are indicated in [ ].</p><p><sup>‡</sup>As defined in: Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. <italic>Ann Neurol</italic> 1991;30:637-649.</p><p><sup>§</sup>Siderosis restricted to 3 or fewer sulci.</p><p><sup>∥</sup>Siderosis affecting at least 4 sulci.</p><p><sup>¶</sup>Other causes of intracerebral hemorrhage: excessive warfarin (international normalization ratio, INR&gt;3.0); antecedent head trauma or ischemic stroke; central nervous system tumor, vascular malformation, or vasculitis; and blood dyscrasia or coagulopathy. INR&gt;3.0 or other nonspecific laboratory abnormalities permitted for diagnosis of possible CAA.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="266" pm="."><plain>Biomarkers and risk factors for cerebral amyloid angiopathy (CAA) and CAA-related disorders </plain></SENT>
</text></p></caption><graphic xlink:href="jos-17-17-i003"/><table-wrap-foot><fn><p><sup>*</sup>Gradient echo T2<sup>*</sup> or susceptibility-weighted images are recommended to detect microhemorrhages or focal superficial siderosis.</p><p><sup>†</sup>Future development of MRI scanners with a higher spatial resolution is necessary to detect cortical microinfarcts.</p><p><sup>‡</sup>Some mutations in the amyloid β-protein precursor (AβPP) and presenilin genes are associated with severe CAA [see review<xref rid="B5" ref-type="bibr">5</xref>].</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
